Cargando…

Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with a poor prognosis. No efficacious treatment options are currently available for patients with advanced metastatic disease with disease progression to standard etoposide, doxorubicin, cisplatin and mitotane (EDP-M) the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laganà, M., Grisanti, S., Ambrosini, R., Cosentini, D., Abate, A., Zamparini, M., Ferrari, V.D., Gianoncelli, A., Turla, A., Canu, L., Terzolo, M., Tiberio, G.A.M., Sigala, S., Berruti, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058897/ https://www.ncbi.nlm.nih.gov/pubmed/35272132 http://dx.doi.org/10.1016/j.esmoop.2022.100422

Ejemplares similares

Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status
por: Turla, Antonella, et al.
Publicado: (2023)

Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen
por: Turla, Antonella, et al.
Publicado: (2022)

Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy
por: Cosentini, Deborah, et al.
Publicado: (2021)

Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?
por: Grisanti, Salvatore, et al.
Publicado: (2021)

Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma
por: Cosentini, Deborah, et al.
Publicado: (2021)

Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells
por: Abate, Andrea, et al.
Publicado: (2020)

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience
por: Laganà, Marta, et al.
Publicado: (2020)

Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma
por: Fiorentini, Chiara, et al.
Publicado: (2019)

Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
por: Grisanti, Salvatore, et al.
Publicado: (2021)

Immunotherapy failure in adrenocortical cancer: where next?
por: Cosentini, Deborah, et al.
Publicado: (2018)

OR12-1 Activity of Abiraterone Acetate in the management of Cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial.
por: Abate, Andrea, et al.
Publicado: (2022)

Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria
por: Ambrosini, Roberta, et al.
Publicado: (2020)

Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines
por: Tamburello, Mariangela, et al.
Publicado: (2023)

THU616 Analysis Of Germline Mutations In Patients With Sporadic Adrenocortical Carcinoma
por: Terzolo, Massimo, et al.
Publicado: (2023)

Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer
por: Rossini, Elisa, et al.
Publicado: (2021)

A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma
por: Sigala, Sandra, et al.
Publicado: (2022)

Adrenocortical Carcinoma
por: Berruti, Alfredo, et al.
Publicado: (2021)

Hyperthermic Intraperitoneal Chemotherapy for Primary or Recurrent Adrenocortical Carcinoma. A Single Center Study
por: Tiberio, Guido Alberto Massimo, et al.
Publicado: (2020)

Correction: Sigala et al. A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma. Cells 2022, 11, 1439
por: Sigala, Sandra, et al.
Publicado: (2023)

Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis
por: Turla, Antonella, et al.
Publicado: (2022)

Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α
por: Rossini, Elisa, et al.
Publicado: (2021)

S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study
por: Elhassan, Y S, et al.
Publicado: (2021)

Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study
por: Delbarba, Andrea, et al.
Publicado: (2023)

Modified GRAS Score for Prognostic Classification of Adrenocortical Carcinoma: An ENSAT Multicentre Study
por: Elhassan, Yasir, et al.
Publicado: (2021)

FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma
por: Tamburello, Mariangela, et al.
Publicado: (2022)

Treatment and outcome of metastatic parathyroid carcinoma: A systematic review and pooled analysis of published cases
por: Alberti, Andrea, et al.
Publicado: (2022)

1693P Accurate triage may be efficacious in selecting patients who could safely continue anticancer therapy during SARS-CoV-2 pandemic
por: Gurizzan, C., et al.
Publicado: (2020)

An update on adrenocortical cell lines of human origin
por: Sigala, Sandra, et al.
Publicado: (2022)

Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic
por: Gurizzan, Cristina, et al.
Publicado: (2021)

Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
por: Basile, Vittoria, et al.
Publicado: (2020)

Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies
por: Amoroso, V., et al.
Publicado: (2023)

Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study
por: Kimpel, Otilia, et al.
Publicado: (2021)

CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells
por: Germano, Antonina, et al.
Publicado: (2018)

Preclinical profile of cabazitaxel
por: Vrignaud, Patricia, et al.
Publicado: (2014)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021)

Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report
por: di Mauro, Pierluigi, et al.
Publicado: (2023)

THU617 Prolonged Exposure To Target Mitotane Concentrations Is Associated With Better Recurrence-free Survival In Patients With Adrenocortical Carcinoma On Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2023)

Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy
por: Pedersini, Rebecca, et al.
Publicado: (2022)

SUN-350 Sterol-O-Acyl Transferase 1 Protein Expression Alone Is Not Sufficient to Predict Response to Mitotane Treatment in Adrenocortical Carcinoma
por: Weigand, Isabel, et al.
Publicado: (2019)

Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
por: Terzolo, Massimo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fe2qvhrh5orptjcioi4n6njf8v